Upstream Bio, Inc. $UPB Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its position in Upstream Bio, Inc. (NASDAQ:UPB) by 25.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,955 shares of the company’s stock after selling 11,535 shares during the quarter. Goldman Sachs Group Inc. owned about 0.06% of Upstream Bio worth $202,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Upstream Bio in the fourth quarter valued at $25,000. New York State Common Retirement Fund purchased a new stake in shares of Upstream Bio during the first quarter valued at $29,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Upstream Bio during the fourth quarter valued at $162,000. XTX Topco Ltd purchased a new stake in shares of Upstream Bio during the first quarter valued at $78,000. Finally, Bank of America Corp DE purchased a new stake in shares of Upstream Bio during the fourth quarter valued at $230,000.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Upstream Bio from a “sell” rating to a “hold” rating in a report on Friday, June 6th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $56.50.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $17.26 on Monday. The stock has a 50-day moving average price of $16.60 and a 200 day moving average price of $11.85. Upstream Bio, Inc. has a 1 year low of $5.14 and a 1 year high of $29.46.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The business had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $0.32 million. Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%. On average, equities analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.